… Natriuretic peptides are fundamental to our understanding of the pathophysiology of heart
failure because they reflect left ventricular … age, kidney function, and heart rhythm, as well as …

… natriuretic peptide (NT-proBNP) has been well established in heart failure (HF), and measurement
of natriuretic peptides for … However, patients with heart failure with preserved ejection …

… entry criteria and outcomes in patients treated with dapagliflozin and empagliflozin, we
assessed the effect of these therapies on cardiovascular death or HHF in patients with LVEF ≤30…

… in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total,
324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (…

… of dapagliflozin for the management of chronic heart failure. We showed that dapagliflozin
… significantly decrease the frequency of cardiovascular death/hospitalization for heart failure, …

… with clinically meaningful improvements in HF-related health status or natriuretic peptides
[15]. The average 6- and 12-week adjusted mean NT-proBNP level was not significantly …

… (N-terminal pro b-type natriuretic peptide) levels with dapagliflozin vs placebo at 12 weeks.
D, Clinically meaningful changes in BNP levels with dapagliflozin vs placebo at 12 weeks. …

… Decrease in B-type natriuretic peptide and increase in plasma renin activity were significant
in each group. Plasma aldosterone concentration, however, was significantly increased in …

… Natriuretic peptides are not an inclusion criterion due to the lack of standardization in AHF
trials, the high obesity rate in the enrollment areas, and rigor of our other criteria in identifying …

… demonstrated that initiation of dapagliflozin in patients with stable chronic HF is associated
with a reduction of LAVI, LV mass and concentration of natriuretic peptides after 6 months. …